Área Oncología

Grupo de Investigación Translacional de Tumores Sólidos Pediátricos

Samuel Navarro Fos

Dr. Navarro received his degree in Medicine and Surgery from the Faculty of Medicine at the University of Valencia in 1980 and went on to obtain his doctorate from the same university in 1987. He completed his training in Bethesda (USA) with a scholarship to conduct pathology laboratory research. He is now a permanent Senior Professor of Pathological Anatomy in the Faculty of Medicine and Odontology in the Pathology Department at the University of Valencia and has directed 13 doctoral thesis students who received magna cum laude honors.

He is the national coordinator of the anatomopathological studies and the International Society of Pediatric Oncology (SIOP) groups; he is a member of the Prognostic and therapeutic targets in the Ewing's family of tumors (PROTHETS) and the Childhood Solid Tumors Cooperative Network (RITSI; Red temática de investigación cooperativa de tumores sólidos infantiles) and is the Principal Investigator in the Cooperative Network of Research against Cancer: Pediatric tumors. 

He has participated in 18 national and international R&D projects, focusing his research activity on morphological, immunophenotypic, and genetic characterization of undifferentiated round sarcoma cells from bone and other soft tissues. His research group has consolidated its place as a Spanish and European group of reference for establishing phenotypic, prognostic, and genetic factors in neuroblastic tumors. His group has also participated as a flagship center, among various national and European centers, in trialing treatment protocols for neuroblastic tumors, in accordance with SIOP guidelines, and he has collaborated with European Laboratories (Prof S. Palman, University of Malmo, Sweden) to study hypoxia and angiogenesis in neuroblastic tumors. In particular, his application of new high-performance technologies for analyzing genetic factors of prognostic value in neuroblastic tumors stands out.

 

  • Análisis genéticos en neuroblastoma. A nivel europeo participamos en el estableciendo de una nomenclatura uniforme, un procedimiento estándar de actuación y estudios de validación de calidad, imprescindibles para obtener y mantener una alta calidad de los resultados de FISH, MLPA y SNPs utilizados para la estratificación terapéutica.
  • Identificación de nuevos factores genéticos con valor pronóstico en los tumores neuroblásticos y esqueletógenos malignos infantiles.
  • Obtención y caracterización de líneas celulares derivadas de tumores en fresco de tumores esqueletógenos infantiles.
  • Establecimiento y caracterización de modelos in vivo de tumores esqueletógenos malignos.
  • Estudios de expresión de marcadores en el carcinoma colorrectal y en tumores sólidos pediatricos.
  • Resultados procedentes del estudio del microambiente tumoral en neuroblastoma.